These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29056424)

  • 1. Implementing near real-time vaccine safety surveillance using the Clinical Practice Research Datalink (CPRD).
    Leite A; Thomas SL; Andrews NJ
    Vaccine; 2017 Dec; 35(49 Pt B):6885-6892. PubMed ID: 29056424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do delays in data availability limit the implementation of near real-time vaccine safety surveillance using the Clinical Practice Research Datalink?
    Leite A; Thomas SL; Andrews NJ
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):25-29. PubMed ID: 29193554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing recording delays in general practice records to inform near real-time vaccine safety surveillance using the Clinical Practice Research Datalink (CPRD).
    Leite A; Andrews NJ; Thomas SL
    Pharmacoepidemiol Drug Saf; 2017 Apr; 26(4):437-445. PubMed ID: 28156036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013-2014 and 2014-2015 seasons.
    Li R; Stewart B; McNeil MM; Duffy J; Nelson J; Kawai AT; Baxter R; Belongia EA; Weintraub E
    Pharmacoepidemiol Drug Saf; 2016 Aug; 25(8):928-34. PubMed ID: 27037540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Near real-time surveillance for Guillain-Barré syndrome after influenza vaccination among the Medicare population, 2010/11 to 2013/14.
    Sandhu SK; Hua W; MaCurdy TE; Franks RL; Avagyan A; Kelman J; Worrall CM; Ball R; Nguyen M
    Vaccine; 2017 May; 35(22):2986-2992. PubMed ID: 28449973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season.
    Kawai AT; Li L; Kulldorff M; Vellozzi C; Weintraub E; Baxter R; Belongia EA; Daley MF; Jacobsen SJ; Naleway A; Nordin JD; Lee GM
    Pharmacoepidemiol Drug Saf; 2014 May; 23(5):548-53. PubMed ID: 24497128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance for Guillain-Barré syndrome after 2015-2016 and 2016-2017 influenza vaccination of Medicare beneficiaries.
    Arya DP; Said MA; Izurieta HS; Perez-Vilar S; Zinderman C; Wernecke M; Alexander M; White T; Su IH; Lufkin B; MaCurdy T; Kelman J; Forshee R
    Vaccine; 2019 Oct; 37(43):6543-6549. PubMed ID: 31515146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance for Guillain-Barré syndrome after influenza vaccination among U.S. Medicare beneficiaries during the 2017-2018 season.
    Perez-Vilar S; Wernecke M; Arya D; Lo AC; Lufkin B; Hu M; Chu S; MaCurdy TE; Kelman J; Forshee RA
    Vaccine; 2019 Jun; 37(29):3856-3865. PubMed ID: 31122853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011.
    Tse A; Tseng HF; Greene SK; Vellozzi C; Lee GM;
    Vaccine; 2012 Mar; 30(11):2024-31. PubMed ID: 22361304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Near real-time vaccine safety surveillance with partially accrued data.
    Greene SK; Kulldorff M; Yin R; Yih WK; Lieu TA; Weintraub ES; Lee GM
    Pharmacoepidemiol Drug Saf; 2011 Jun; 20(6):583-90. PubMed ID: 21538670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A simulation study of the statistical power and signaling characteristics of an early season sequential test for influenza vaccine safety.
    Forshee RA; Hu M; Arya D; Perez-Vilar S; Anderson SA; Lo AC; Swarr M; Wernecke M; MaCurdy T; Chu S; Kelman J
    Pharmacoepidemiol Drug Saf; 2019 Aug; 28(8):1077-1085. PubMed ID: 31222967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines.
    Dodd CN; Romio SA; Black S; Vellozzi C; Andrews N; Sturkenboom M; Zuber P; Hua W; Bonhoeffer J; Buttery J; Crawford N; Deceuninck G; de Vries C; De Wals P; Gutierrez-Gimeno MV; Heijbel H; Hughes H; Hur K; Hviid A; Kelman J; Kilpi T; Chuang SK; Macartney K; Rett M; Lopez-Callada VR; Salmon D; Gimenez-Sanchez F; Sanz N; Silverman B; Storsaeter J; Thirugnanam U; van der Maas N; Yih K; Zhang T; Izurieta H;
    Vaccine; 2013 Sep; 31(40):4448-58. PubMed ID: 23770307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observational safety study of specific outcomes after trivalent cell culture seasonal influenza vaccination (Optaflu
    Hall GC; Davies PTG; Karim MY; Haag MDM; O'Leary C
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):52-58. PubMed ID: 29152808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous sequential boundaries for vaccine safety surveillance.
    Li R; Stewart B; Weintraub E; McNeil MM
    Stat Med; 2014 Aug; 33(19):3387-97. PubMed ID: 24691986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005).
    Souayah N; Nasar A; Suri MF; Qureshi AI
    J Clin Neuromuscul Dis; 2009 Sep; 11(1):1-6. PubMed ID: 19730016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between Guillain-Barré syndrome, influenza-related hospitalizations, and influenza vaccine coverage.
    Iqbal S; Li R; Gargiullo P; Vellozzi C
    Vaccine; 2015 Apr; 33(17):2045-9. PubMed ID: 25749247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-vaccination healthcare attendance rate as a proxy measure for syndromic surveillance of adverse events following immunisation.
    Mesfin YM; Cheng AC; Enticott J; Lawrie J; Buttery J
    Aust N Z J Public Health; 2021 Apr; 45(2):101-107. PubMed ID: 33617131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guillain-Barré syndrome following influenza vaccination.
    Haber P; DeStefano F; Angulo FJ; Iskander J; Shadomy SV; Weintraub E; Chen RT
    JAMA; 2004 Nov; 292(20):2478-81. PubMed ID: 15562126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome.
    Miller ER; McNeil MM; Moro PL; Duffy J; Su JR
    Vaccine; 2020 Nov; 38(47):7458-7463. PubMed ID: 33039207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.